XNAS · Healthcare · Biotechnology
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.83 | -0.90 | -8.43% | $0 | ❌ Miss | +0.00% | +0.69% | — |
| 2026-05-14 | Q1 2026 | -0.75 | -0.79 | -5.33% | $0 | ❌ Miss | +0.84% | +141.18% | +46.22% |
| 2026-03-26 |
| Q4 2025 |
| -1.92 |
| -0.42 |
| +78.12% |
| $0 |
| ✅ Beat |
| +0.00% |
| -4.55% |
| +18.18% |
| 2025-11-06 | Q3 2025 | -0.25 | -0.14 | +44.00% | $0 | ✅ Beat | — | — | — |
| 2025-03-20 | Q4 2024 | -0.89 | -0.32 | +64.04% | $0 | ✅ Beat | +0.00% | +0.65% | -52.74% |
| 2024-11-07 | Q3 2024 | -0.73 | -0.55 | +24.66% | $0 | ✅ Beat | — | — | -9.02% |
| 2024-08-14 | Q2 2024 | -1.12 | -1.85 | -65.18% | $0 | ❌ Miss | — | — | — |
| 2024-03-28 | Q4 2023 | -0.78 | -1.02 | -30.77% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.